

## REMARKS

### Restriction Requirement

The Examiner states that restriction of the pending claims into one of the following four patentably distinct groups is required under 35 U.S.C. § 121.

**Group I:** Claims 1-10 and 12-27, drawn to compounds of formula (I) where compounds are represented by compounds disclosed in Table 1 in which R' does not represent a heterocyclic group, pharmaceutical compositions containing these compounds, and a method of using these compounds;

**Group II:** Claims 1-27, drawn to compounds of formula (I) where compounds are represented by compounds disclosed in Table 1 in which R' represents 5-membered heterocyclic ring containing one O atom as heteroatom including fused ring system, pharmaceutical compositions containing these compounds, and a method of using these compounds;

**Group III:** Claims 1-27, drawn to compounds of formula (I) where compounds are represented by compounds disclosed in Table 1 in which R' represents 6-membered heterocyclic ring containing two O atoms as heteroatoms, pharmaceutical compositions containing these compounds, and a method of using these compounds; and

**Group IV:** Claims 1-27, drawn to compounds of formula (I) directed to compounds other than defined above for groups I, II, and III, pharmaceutical compositions containing these compounds, and a method of using these compounds.

In response, applicants elect without traverse the claims of **Group I** for further initial substantive prosecution on the merits.

This election is made expressly without waiver of applicants' rights to file for and obtain claims directed to the unelected subject matter in either this application or in divisional or continuing applications claiming priority and benefit from this application under 35 U.S.C. § 120.

**Amendments to the Claims**

In view of applicants' election herein of Group 1, and solely to advance prosecution of this application towards allowance, applicants have amended the pending claims to cancel unelected subject matter.

Accordingly, applicants have amended claim 1 and canceled claim 11 in order to cancel, without prejudice, the unelected subject matter.

Claim 15 has been amended to conform to its antecedents in amended claim 1.

Claim 17 has been amended to recite particular species of the elected subject matter, as well as to cancel the species that were directed to the unelected subject matter. Claims 18-22, which were directed to unelected subject matter, have been canceled without prejudice. Support for the species recited in amended claim 17 can be found at, for example, the correspondingly numbered compounds on pages 23-47 of the specification.


Claim 23 has been amended to remove references to the canceled claims.

Applicants submit that these amendments do not introduce new matter, and therefore request their entry.

Claims 1-10, 12-17, and 23-27 remain in this application for further examination.

Applicants request favorable consideration of the application and early allowance of the pending claims. Should the Examiner feel that a telephone conference with applicants' representatives would assist the Examiner, he is invited to telephone the undersigned at anytime.

Respectfully submitted,



James F. Halcy, Jr. (Reg. No. 27,794)  
Karon Mangasarian (Reg. No. 43,772)  
Attorneys for Applicants

Tae Bum Shin (Ltd. Reg. No. L0091)  
Agent for Applicants

FISH & NEAVE IP GROUP  
ROPES & GRAY LLP  
Customer No. 1473  
1251 Avenue of the Americas  
New York, New York 10020-1105  
Tel.: (650) 617-4000 (CA)  
Fax: (212) 596-9090 (NY)